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INTRODUCTION 
  The term “secondary dyslipidemias” is used to describe the quantitative and/or qualitative alterations in lipoprotein 
metabolism that complicate the course of other medical disorders. Although the precise prevalence of secondary dyslipidemias 
has not been determined, the increasing incidence of the conditions that predispose to their development (such as obesity, 
diabetes mellitus, malignancies, end stage renal disease etc) implies that these alterations are very common in the every day 
clinical practice. Several lines of evidence suggest that the identification and appropriate management of secondary 
dyslipidemias is of paramount importance. Like primary dyslipidemias, the secondary changes in lipid metabolism significantly 
increase the risk for cardiovascular events [1, 2] as well as for other disease-specific complications. For example, the 
dyslipidemia of chronic kidney diseases may accelerate the deterioration of renal function in patients with renal failure [3], 
whereas diabetic dyslipidemia may increase the risk of acute pancreatitis in genetically predisposed individuals [4]. On the 
other hand, since the improvement of the underlying disease (if possible) usually results in the correction (at least in part) of 
lipid abnormalities, the proper identification of a secondary cause of dyslipidemia may help to the avoidance of unnecessary 
hypolipidemic treatment. In addition, some secondary causes of dyslipidemia (such as hypothyroidism and renal failure) may 
increase the risk of serious and potentially fatal adverse events after hypolipidemic drug administration [5, 6], thus their 
exclusion is obligatory prior to the institution of lipid-lowering therapy. Finally, the presence of dyslipidemia or its response to 
the conventional medical treatment may represent the first clinical sigh of an important underlying medical condition [7]. 
  The most common causes of secondary dyslipidemias as well as the few simple laboratory tests that along with a detailed 
medical history and a throughout physical examination are needed for their exclusion are presented in the Table 1. This 
supplement issue of the Open Cardiovascular Medicine Journal is dedicated to the most common forms of secondary 
dyslipidemias. The pathophysiology, clinical features and the relevant therapeutic options are discussed extensively. We 
believe that this knowledge is of importance not only for lipid specialists but also for every doctor that deals with dyslipidemic 
individuals in the primary care setting.  
Table 1.  Common Causes of Secondary Dyslipidemias and Their Laboratory Markers 
Condition Laboratory  test 
Diabetes mellitus  Fasting glucose 
Hypothyroidism  Thyroid stimulating hormone (TSH) 
Chronic kidney disease 
Serum creatinine  
Estimated Glomerular filtration rate (eGFR) 
Nephrotic syndrome  Dipstick urine examination 
Cholestasis Alkaline  phosphatase Editorial  The Open Cardiovascular Medicine Journal, 2011, Volume 5    23 
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